FDA Gives Full Approval to Encorafenib Combo for BRAF V600E Metastatic Colorectal Cancer

n

The US FDA has granted traditional full approval for Encorafenib (Braftovi) in combination with Cetuximab (Erbitux) and fluorouracil-based chemotherapy for adults with metastatic colorectal cancer (mCRC) that has a BRAF V600E mutation confirmed by an FDA-authorized test. 

This matters because BRAF V600E–mutated mCRC is a distinct subtype that typically requires a targeted approach, and this approval formalizes a first-line targeted regimen supported by mature phase 3 survival data.

What traditional approval means

Traditional approval means the FDA has determined there is a verified clinical benefit (not just a surrogate endpoint) based on the submitted evidence. In this case, the decision was supported by results from the phase 3 BREAKWATER trial. 

It also builds on the earlier accelerated approval the FDA granted in December 2024 for an encorafenib-based combination in this setting. 

Who is eligible

This approval is for:

• Adults with metastatic colorectal cancer
• The tumor has a BRAF V600E mutation
• Mutation is identified using an FDA-authorized test 

One commonly referenced companion diagnostic is the therascreen BRAF V600E RGQ PCR Kit. 

What regimen was approved

The FDA approval is for:

• Encorafenib plus cetuximab
• Combined with fluorouracil-based chemotherapy

The FDA notice and reporting on the approval describe fluorouracil-based backbones, such as mFOLFOX6 and FOLFIRI, as part of the studied combinations in BREAKWATER. 

BREAKWATER trial in simple terms

BREAKWATER (NCT04607421) is a phase 3, randomized trial in previously untreated (treatment-naive) BRAF V600E–mutant metastatic colorectal cancer. 

Key results that supported full approval (reported for the mFOLFOX6 cohort comparison)

Compared with standard chemotherapy approaches, the encorafenib + cetuximab + mFOLFOX6 arm showed:

• Median progression-free survival (PFS): 12.8 months vs 7.1 months (HR 0.53) 
• Median overall survival (OS): 30.3 months vs 15.1 months (HR 0.49) 
• Overall response rate (ORR): 61% vs 40% 

Additional supportive response data (FOLFIRI cohort, as reported)

In a cohort comparison involving FOLFIRI-based treatment, the reported ORR was 64% vs 39%. 

Why BRAF testing is now even more important

This approval makes BRAF V600E status a front-line decision point for metastatic CRC treatment planning. If the mutation is present, a targeted regimen becomes a major option right away rather than later. 

Practical takeaway for patient education:

• Ask whether your tumor has been tested for BRAF V600E
• Confirm which test was used and whether it is FDA-authorized

What patients may ask their oncologist?

• Do I have a BRAF V600E mutation, and how was it tested? 
• Is this targeted combination appropriate as my first-line treatment? 
• Which chemo backbone are you recommending with the targeted drugs, and why?
• What side effects should I expect, and what monitoring plan will we use?

Key takeaway

Full FDA approval of encorafenib + cetuximab + fluorouracil-based chemotherapy for BRAF V600E–mutant metastatic colorectal cancer is a major step toward biomarker-driven, first-line treatment in this aggressive subtype, supported by phase 3 data showing improved PFS, OS, and response compared with standard therapy.

References

1. FDA. FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation. February 24, 2026. (U.S. Food and Drug Administration)
2. CancerNetwork. FDA grants traditional approval to encorafenib in BRAF-mutated CRC. February 2026. (cancernetwork.com)
3. Pfizer press release. US FDA grants full approval to Braftovi combination; BREAKWATER trial description. February 2026. (Pfizer)
4. QIAGEN. Therascreen BRAF V600E RGQ PCR Kit product information. (qiagen.com)
5. FDA CDRH. Premarket Approval page for therascreen BRAF V600E RGQ PCR Kit (P190026). (FDA Access Data)
6. ASCO Publications. BREAKWATER first-line encorafenib + cetuximab + mFOLFOX6 abstract (JCO supplement). (ASCO Publications)